Inmode Ltd. - (INMD) closed at $13.27 on November 13, 2026, up 0.6% from the previous close, on volume of 555,116 shares (30-day average 538,230).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | 3 Leg Call/Put Combo Calendar with Ratio | 20-Nov-2616[2x] P|19-Feb-2716 C|21-Jan-2815[2x] P | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Canaccord Genuity Keeps Their Hold Rating on InMode (INMD)
TipRanks (Fri, 13-Nov 9:07 AM ET)
InMode Reports Third-Quarter 2026 Revenue of $92.1 Million
TipRanks (Thu, 12-Nov 7:20 AM ET)
TipRanks (Thu, 12-Nov 6:11 AM ET)
Options Volatility and Implied Earnings Moves Today, November 11, 2026
TipRanks (Wed, 11-Nov 7:05 AM ET)
InMode reports Q3 earnings above street expectations
Seeking Alpha News (Wed, 11-Nov 7:04 AM ET)
PRNewswire (Wed, 11-Nov 7:00 AM ET)
Here are the major earnings before the open Wednesday
Seeking Alpha News (Tue, 10-Nov 6:00 PM ET)
InMode Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 10-Nov 10:50 AM ET)
Earnings Week Ahead: CSCO, CRWV, PLUG, ALC, AMAT, ACB, RKLB, ASTS, and more
Seeking Alpha News (Sun, 8-Nov 8:07 AM ET)
Business Wire (Mon, 19-Oct 8:00 AM ET)
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
Inmode Ltd. - trades on the NASDAQ stock market under the symbol INMD.
As of November 13, 2026, INMD stock price climbed to $13.27 with 555,116 million shares trading.
INMD has a beta of 0.49, meaning it tends to be less sensitive to market movements. INMD has a correlation of 0.05 to the broad based SPY ETF.
INMD has a market cap of $762.77 million. This is considered a Small Cap stock.
Last quarter Inmode Ltd. - reported $92 million in Revenue and $.37 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.05.
In the last 3 years, INMD traded as high as $26.80 and as low as $12.72.
The top ETF exchange traded funds that INMD belongs to (by Net Assets): IEFA, SCZ, IXUS, IZRL, EIS.
INMD has underperformed the market in the last year with a return of -9.2%, while the SPY ETF gained +11.5%. In the last 3 month period, INMD fell short of the market, returning -12.9%, while SPY returned -2.1%. However, in the most recent 2 weeks INMD has outperformed the stock market by returning -1.8%, while SPY returned -1.9%.
INMD support price is $12.96 and resistance is $13.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INMD shares will trade within this expected range on the day.
